February 2007 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

February 2007

Pharmaceutical Technology


REGULATIONS/DISTRIBUTION

US Court Delays FDA Drug-Pedigree Requirements


www.activis.com
Rockville, MD (Dec. 18)—The US Food and Drug Administration ( http://www.fda.gov/) modified its requirements for drug pedigrees accompanying wholesale pharmaceutical transactions, following a US District Court preliminary injunction barring the agency from enforcing certain provisions of the rule that was to have gone into effect on Dec. 1.

The injunction, filed on Dec. 11 by Judge Joanna Seybert of the US District Court for the Eastern District of New York (Brooklyn, NY and Central Islip, NY, http://www.nyed.uscourts.gov/), blocks the enforcement of a set of rules [21 CFR 203.50(a)(1-6)] that would have required secondary wholesalers (those who do not have formal authorized-distributor relationships with manufacturers) to supply pedigrees tracing the chain of custody all the way to the maker. The enjoined rules also would have required the pedigree to include data such as lot and control numbers, dosage, container size, and number of containers.

Other pedigree requirements remain in effect, FDA says, and wholesalers can comply by providing a pedigree that tracks the drug to initial sale by an authorized distributor. Though the injunction strictly applies only to the Eastern District of New York, to avoid the chaos that would follow a regional patchwork of requirements, FDA indicated that it will apply the Eastern District standard throughout its jurisdiction (1).

The lawsuit was filed Sept. 20 by online discount outlet RxUSA Wholesale, Inc. (Port Washington, NY, http://www.rxusa.com/) and six other regional secondary wholesale operations. The suit claims that contradictions in the Prescription Drug Marketing Act (as modified by the Prescription Drug Amendments of 1992) made it effectively impossible for wholesalers to comply with the law or the regulations derived from it. Essentially, the law and the regulation required secondary wholesalers to obtain and pass on pedigrees stretching back to the original manufacturer, but did not require authorized distributors (from whom the secondary market buys its products) to provide pedigrees linking the lots back to the manufacturer.

In issuing the injunction, Judge Seybert confirmed a Magistrate Judge's "Recommendation and Report," which held that implementing the rules as they were due to go into effect Dec. 1 would have destroyed the plaintiffs' business. Thus, FDA is barred from enforcing the rules until the suit is tried and decided.

References

1. US Food and Drug Administration, Guidance for Industry: Prescription Drug Marketing Act (PDMA) Requirements, (FDA, Rockville, MD, 2006), http:// http://www.fda.gov/CDER/regulatory/PDMA/PDMA_qa.pdf, accessed Jan. 17, 2007.

Douglas McCormick


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here